127 related articles for article (PubMed ID: 36564983)
21. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
22. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.
Violante R; Oliveira JH; Yoon KH; Reed VA; Yu MB; Bachmann OP; Lüdemann J; Chan JY
Diabet Med; 2012 Nov; 29(11):e417-24. PubMed ID: 22375612
[TBL] [Abstract][Full Text] [Related]
23. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
[TBL] [Abstract][Full Text] [Related]
26. Prusogliptin (DBPR108) monotherapy in treatment-naïve patients with type 2 diabetes: A randomized, double-blind, active and placebo-controlled, phase 3 study.
Wang W; Guo X; Zhang C; Ning T; Ma G; Huang Y; Jia R; Zhou D; Cao M; Zhang T; Yao L; Yuan J; Chen L;
Diabetes Obes Metab; 2024 Apr; 26(4):1321-1332. PubMed ID: 38221859
[TBL] [Abstract][Full Text] [Related]
27. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Hanefeld M; Herman GA; Wu M; Mickel C; Sanchez M; Stein PP;
Curr Med Res Opin; 2007 Jun; 23(6):1329-39. PubMed ID: 17559733
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
[TBL] [Abstract][Full Text] [Related]
29. Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).
Park SE; Lee BW; Kim JH; Lee WJ; Cho JH; Jung CH; Lee SH; Suh S; Hur GC; Kim SH; Jang YH; Park CY;
Diabetes Obes Metab; 2017 Jun; 19(6):892-896. PubMed ID: 28058753
[TBL] [Abstract][Full Text] [Related]
30. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
[TBL] [Abstract][Full Text] [Related]
31. A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.
Gantz I; Okamoto T; Ito Y; Okuyama K; O'Neill EA; Kaufman KD; Engel SS; Lai E;
Diabetes Obes Metab; 2017 Nov; 19(11):1602-1609. PubMed ID: 28449368
[TBL] [Abstract][Full Text] [Related]
32. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.
Scheen AJ; Charpentier G; Ostgren CJ; Hellqvist A; Gause-Nilsson I
Diabetes Metab Res Rev; 2010 Oct; 26(7):540-9. PubMed ID: 20824678
[TBL] [Abstract][Full Text] [Related]
34. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.
Jadzinsky M; Pfützner A; Paz-Pacheco E; Xu Z; Allen E; Chen R;
Diabetes Obes Metab; 2009 Jun; 11(6):611-22. PubMed ID: 19515181
[TBL] [Abstract][Full Text] [Related]
35. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
Rizzo MR; Barbieri M; Marfella R; Paolisso G
Diabetes Care; 2012 Oct; 35(10):2076-82. PubMed ID: 22688551
[TBL] [Abstract][Full Text] [Related]
36. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Lim S; Han KA; Yu J; Chamnan P; Kim ES; Yoon KH; Kwon S; Moon MK; Lee KW; Kim DJ; Kim M; Wongtanate M; Kim EY; Kim SH; Lee MK;
Diabetes Obes Metab; 2017 Jan; 19(1):87-97. PubMed ID: 27619558
[TBL] [Abstract][Full Text] [Related]
38. A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
Kitazawa M; Katagiri T; Suzuki H; Matsunaga S; H Yamada M; Ikarashi T; Yamamoto M; Furukawa K; Iwanaga M; Hatta M; Fujihara K; Yamada T; Tanaka S; Sone H
Diabetes Obes Metab; 2021 Mar; 23(3):811-821. PubMed ID: 33416200
[TBL] [Abstract][Full Text] [Related]
39. Vascular and metabolic effects of ipragliflozin versus sitagliptin (IVS) in type 2 diabetes treated with sulphonylurea and metformin: IVS study.
Kang SM; Yun HM; Sohn M; Lim S
Diabetes Obes Metab; 2023 Jul; 25(7):1922-1931. PubMed ID: 36932823
[TBL] [Abstract][Full Text] [Related]
40. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
